Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

Mainstay Medical announces US FDA approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain

News
- 22/06/2020
U.S. commercialization expected to begin in the first half of 2021 Continues positive momentum for Mainstay, with increasing commercial footprint in Europe and expected launch in Australia in early 2021 Dublin, Ireland: 22 June 2020…
Read more

Confo Therapeutics expands Board with appointment of Rob Scott as Independent Director

News
- 10/06/2020
Ghent, Belgium: 10 June 2020 - Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr Scott’s career…
Read more

Team
Dr Jos B. Peeters
Chairman of the Executive Committee - Responsible for venture capital, finance and IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.